Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Recruiting
Observational Study
AL Amyloidosis
Smoldering Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 760 (estimated)
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to:
1. Implement a biomarker-based screening strategy to promote early diagnosis of AL amyloidosis among at-risk patients, including patients with monoclonal gammopathy of undetermined significance, MGUS, and altered free light chain…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
PART A
Inclusion Criteria:
* diagnosis of MGUS with altered FLCR or SMM;
* treatment-naïve;
* age ≥18 years;
* ability to understand and willingness to sign an informed consent;
* planned follow-up at participating center.
Exclusion Criteria:
* Diagnosis of symptomatic monoclonal gammopathies;
*…
Contacts
No contact information available.